Overview
Cortexyme develops small-molecule therapeutics targeting bacterial pathogens linked to Alzheimer's disease neuroinflammation and neurodegeneration.
More in Neuropharmaceuticals
Latest industry news
ReVision Implant Secures €4 Million to Advance Neural Vision Restoration Technology
2026-10-15 · Funding
NIH-Backed Device Gives People With Paralysis a New Path to Communication
2026-10-14 · Research
ABILITY Neurotech Begins Clinical Testing of Its Brain-Computer Interface System
2026-10-13 · Research
Flourish Emerges From Stealth With Bezos and Google Ventures Backing to Decode the Nervous System
2026-10-12 · Funding
Company details
Category
💊 Neuropharmaceuticals
Location
San Francisco, CA, USA
Funding
$108M raised (NASDAQ: CRTX)
Website
www.cortexyme.comListed
2026-07-06
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →